In regards to GIA pipeline, I saw some comments about how they would need to take much of the future cash flow and buy a pipeline.
With all the discussion about supply and the difficulty in producing EPA how many companies or segments of companies can actually produce Vascepa at a low cost? Would it make sense for Amarin to, instead of buying another company in hopes of replacing Vascepa revenue in 2029, take the cash flow and purchase or invest a majority into the largest suppliers of Vascepa?
Could they tie up the majority of inventory that way or is that not feasible, assuming multi billion a year in cash flow from Vascepa?
As we see from the recent acquisition, buying a pipeline is expensive and fraught with risk of failure.
If they GIA and IF they successfully get to minimum $5 billion peak sales they will have billions in cash flow before generics, what would really be the best use of these funds? R+D on Vascepa in other indications? Not sure what that gets them, they'd only have a few years before generics to cash in on most of those other indications if they come thru, and don't sell me they get exclusive years in new indications, good luck stopping generic prescriptions for those indications.
At least some of the Money might be better spent maximizing the Vascepa revenue as long as possible, and maybe have multi pronged approach, R&D Vascepa, acquisition of small pipeline AND lock up supply, all seems very expensive though.
